Alessandro Rambaldi to Middle Aged
This is a "connection" page, showing publications Alessandro Rambaldi has written about Middle Aged.
Connection Strength
0.184
-
Long-term follow-up of recovered MPN patients with COVID-19. Blood Cancer J. 2021 06 16; 11(6):115.
Score: 0.015
-
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia. 2021 02; 35(2):485-493.
Score: 0.015
-
Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab. Immunobiology. 2020 11; 225(6):152001.
Score: 0.014
-
Effect of novel agents on the risk of early death of newly diagnosed symptomatic multiple myeloma patients: A single Centre retrospective analysis. Am J Hematol. 2019 01; 94(1):E11-E13.
Score: 0.013
-
Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2017 Dec; 23(12):2070-2078.
Score: 0.012
-
Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. J Hematol Oncol. 2017 02 22; 10(1):54.
Score: 0.011
-
Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas. J Clin Oncol. 2016 11 20; 34(33):4015-4022.
Score: 0.011
-
Covid-19 and gender: lower rate but same mortality of severe disease in women-an observational study. BMC Pulm Med. 2021 Mar 20; 21(1):96.
Score: 0.004
-
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. Blood Cancer J. 2021 02 04; 11(2):21.
Score: 0.004
-
At the peak of COVID-19 age and disease severity but not comorbidities are predictors of mortality: COVID-19 burden in Bergamo, Italy. Panminerva Med. 2021 Mar; 63(1):51-61.
Score: 0.004
-
Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19. Nat Immunol. 2021 01; 22(1):19-24.
Score: 0.004
-
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 2020 09; 34(9):2354-2363.
Score: 0.004
-
Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia. Hematology. 2019 Dec; 24(1):337-348.
Score: 0.003
-
Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group. Am J Hematol. 2020 01; 95(1):E1-E3.
Score: 0.003
-
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO). Biol Blood Marrow Transplant. 2019 12; 25(12):2388-2397.
Score: 0.003
-
Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remission. Am J Hematol. 2019 02; 94(2):231-239.
Score: 0.003
-
Impact of anti-thymocyte globulin on results of allogeneic peripheral blood stem cell transplantation for patients with Philadelphia-positive acute lymphoblastic leukaemia: An analysis by the Acute Leukemia Working Party of the EBMT. Eur J Cancer. 2019 01; 106:212-219.
Score: 0.003
-
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. Blood Cancer J. 2018 09 21; 8(10):89.
Score: 0.003
-
Phase I study of the heparanase inhibitor roneparstat: an innovative approach for ultiple myeloma therapy. Haematologica. 2018 10; 103(10):e469-e472.
Score: 0.003
-
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. Haematologica. 2018 09; 103(9):e392-e394.
Score: 0.003
-
The spleen of patients with myelofibrosis harbors defective mesenchymal stromal cells. Am J Hematol. 2018 05; 93(5):615-622.
Score: 0.003
-
Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia. 2018 05; 32(5):1200-1210.
Score: 0.003
-
Access to alternative donor hematopoietic search and transplantation for acute leukemia in different macro-regions of Italy. A GITMO/IBMDR study. Bone Marrow Transplant. 2018 03; 53(3):291-299.
Score: 0.003
-
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. J Clin Oncol. 2018 02 01; 36(4):310-318.
Score: 0.003
-
Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion. Biol Blood Marrow Transplant. 2018 03; 24(3):507-513.
Score: 0.003
-
Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. Clin Infect Dis. 2017 Nov 13; 65(11):1884-1896.
Score: 0.003
-
Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. Leuk Res. 2017 12; 63:34-40.
Score: 0.003
-
Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. Blood. 2017 10 12; 130(15):1768-1771.
Score: 0.003
-
Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen. Biol Blood Marrow Transplant. 2017 Jul; 23(7):1102-1109.
Score: 0.003
-
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study. J Clin Oncol. 2017 Jun 01; 35(16):1795-1802.
Score: 0.003
-
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood. 2017 06 15; 129(24):3227-3236.
Score: 0.003
-
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017 03 02; 376(9):836-847.
Score: 0.003
-
Validation of the acute leukemia-EBMT score for prediction of mortality following allogeneic stem cell transplantation in a multi-center GITMO cohort. Am J Hematol. 2017 May; 92(5):429-434.
Score: 0.003
-
The effect of arterial hypertension on thrombosis in low-risk polycythemia vera. Am J Hematol. 2017 Jan; 92(1):E5-E6.
Score: 0.003
-
CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features. Haematologica. 2017 03; 102(3):529-540.
Score: 0.003
-
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients. Am J Hematol. 2016 09; 91(9):918-22.
Score: 0.003
-
A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes. Br J Haematol. 2009 Dec; 147(5):681-5.
Score: 0.002
-
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007 Aug 01; 110(3):840-6.
Score: 0.001